A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
|
|
- Patrick Fox
- 6 years ago
- Views:
Transcription
1 A Phase II Study of With or Without Bevacizumab vs in Untreated Metastatic Renal Cell Carcinoma Patients David McDermott, 1 Michael Atkins, 2 Robert Motzer, 3 Brian Rini, 4 Bernard Escudier, 5 Lawrence Fong, 6 Richard W. Joseph, 7 Sumanta Pal, 8 Mario Sznol, 9 John Hainsworth, 10 Walter M. Stadler, 11 Thomas Hutson, 12 Alain Ravaud, 13 Sergio Bracarda, 14 Cristina Suarez, 15 Toni Choueiri, 16 YounJeong Choi, 17 Mahrukh A. Huseni, 17 Gregg D. Fine, 17 Thomas Powles 18 1 Beth Israel Deaconess Medical Center, Boston, MA; 2 Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; 3 Memorial Sloan Kettering Cancer Center, New York, NY; 4 Cleveland Clinic, Cleveland, OH; 5 Gustave Roussy, Villejuif, France; 6 University of California, San Francisco School of Medicine, San Francisco, CA; 7 Mayo Clinic Hospital Florida, Jacksonville, FL; 8 City of Hope Comprehensive Cancer Center, Duarte, CA; 9 Yale School Of Medicine, New Haven, CT; 10 Sarah Cannon Research Institute, Nashville, TN; 11 University of Chicago Medicine, Chicago, IL; 12 Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX; 13 CHU Hopitaux de Bordeaux - Hôpital Saint-André, Bordeaux, France; 14 Ospedale San Donato, Arezzo, Italy; 15 Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; 16 Dana-Farber Cancer Institute, Boston, MA; 17 Genentech, Inc., South San Francisco, CA, USA; 18 Barts Cancer Institute, Queen Mary University of London, London, UK
2 Shifting the Balance Toward Anti-Cancer Immunity With Combined VEGF/PD-L1 Blockade Anti-Cancer Immunity 2 PD-L1, programmed death-ligand 1; VEGF, vascular endothelial growth factor. Finke, Clin Cancer Res. 2008; McDermott, J Clin Oncol. 2016; Wallin. Nat Commun McDermott D, et al. IMmotion150 biomarkers: AACR 2017
3 Shifting the Balance Toward Anti-Cancer Immunity With Combined VEGF/PD-L1 Blockade Anti-Cancer Immunity 3 Bevacizumab PD-L1, programmed death-ligand 1; VEGF, vascular endothelial growth factor. Finke, Clin Cancer Res. 2008; McDermott, J Clin Oncol. 2016; Wallin. Nat Commun McDermott D, et al. IMmotion150 biomarkers: AACR 2017
4 CD8 IHC + Bevacizumab A Phase Ib study in first-line mrcc showed anti-tumor activity and a tolerable safety profile for atezolizumab + bevacizumab 1,2 Sequential tumor biopsies provided preliminary evidence of enhanced anti-tumor immune responses following treatment with bevacizumab and atezolizumab + bevacizumab 2 Pre-treatment Post bevacizumab Post atezolizumab + bevacizumab 1. Sznol, ASCO GU, Wallin, Nat Commun, Figures reprinted from Wallin JJ, et al. Nat Commun. 2016;7: The Authors 2016; licensed under a Creative Commons Attribution 4.0 International License. Presented by: Dr. Thomas Powles
5 IMmotion150 (Phase II) Trial Design Treatment naive, locally advanced or metastatic RCC N = 305 Stratification: Prior nephrectomy PD-L1 IHC expression ( 5% IC level) MSKCC risk category R 1:1:1 First-line treatment 1200 mg IV + bevacizumab 15 mg/kg q3w 1200 mg IV q3w 50 mg (4 wk on, 2 wk off) PD Crossover treatment permitted a + bevacizumab + bevacizumab The coprimary endpoints are PFS (RECIST v1.1 by IRF) in ITT and PD-L1+ patients IMmotion150 was designed to be hypothesis generating and inform the trial design of the Phase III study IMmotion151 Amendments included: Based on Phase 1a data, the definition of PD-L1 positivity was revised from 5% to 1% of IC expressing PD-L1 1 In addition to ITT patients, PD-L1+ patients were included in the coprimary endpoint of IRF-assessed PFS, after interim analyses IC, tumor-infiltrating immune cells; IRF, independent review facility. 1. McDermott JCO a Crossover from atezolizumab monotherapy not allowed in Europe. Presented by: Dr. Thomas Powles
6 Baseline Demographics (ITT) n = bevacizumab n = 101 n = 103 Age, median (range), y 61 (25-85) 62 (32-88) 61 (27-81) Male, n (%) 79 (78%) 74 (73%) 77 (75%) KPS 80, n (%) 94 (93%) 99 (99%) 101 (99%) Predominant clear cell histology, n (%) 96 (96%) 97 (96%) 95 (92%) Sarcomatoid component, n (%) 14 (14%) 15 (15%) 16 (15%) Prior nephrectomy, n (%) 88 (87%) 88 (87%) 89 (86%) MSKCC risk category, n (%) Favorable (0) 21 (21%) 30 (30%) 26 (25%) Intermediate (1 or 2) 70 (69%) 62 (61%) 69 (67%) Poor ( 3) 10 (10%) 9 (9%) 8 (8%) 1% of IC expressing PD-L1 (PD-L1+), n (%) 60 (59%) 50 (50%) 54 (52%) Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo. Presented by: Dr. Thomas Powles
7 IRF-Assessed PFS ITT + bevacizumab Atezo + bev vs sunitinib Atezo vs sunitinib Stratified HR (95% CI) 1.00 (0.69, 1.45) 1.19 (0.82, 1.71) P Value a Atezo, atezolizumab; Bev, bevacizumab. a P values are for descriptive purposes only and not adjusted for multiple comparisons. Presented by: Dr. Thomas Powles
8 IRF-Assessed PFS ITT + bevacizumab Atezo: 6.1 mo (5.4, 13.6) : 8.4 mo (7.0, 14.0) Atezo + bev vs sunitinib Atezo vs sunitinib Stratified HR (95% CI) 1.00 (0.69, 1.45) 1.19 (0.82, 1.71) P Value a Atezo + bev: 11.7 mo (8.4, 17.3) a P values are for descriptive purposes only and not adjusted for multiple comparisons. Presented by: Dr. Thomas Powles
9 IRF-Assessed PFS 1% of IC Expressing PD-L1 + bevacizumab Atezo + bev vs sunitinib Atezo vs sunitinib Stratified HR (95% CI) 0.64 (0.38, 1.08) 1.03 (0.63, 1.67) P Value a a P values are for descriptive purposes only and not adjusted for multiple comparisons. Presented by: Dr. Thomas Powles
10 IRF-Assessed PFS 1% of IC Expressing PD-L1 + bevacizumab Atezo: 5.5 mo (3.0, 13.9) : 7.8 mo (3.8, 10.8) Atezo + bev: 14.7 mo (8.2, 25.1) Atezo + bev vs sunitinib Atezo vs sunitinib Stratified HR (95% CI) 0.64 (0.38, 1.08) 1.03 (0.63, 1.67) P Value a a P values are for descriptive purposes only and not adjusted for multiple comparisons. Presented by: Dr. Thomas Powles
11 IRF-Assessed PFS in Key Subgroups + Bevacizumab vs Sarcomatoid Liver metastasis MSKCC risk IC expressing PD-L1 Baseline Factor Yes No Yes No Favorable Intermediate Poor < 1% 1% and < 5% 5% and < 10% 10% All patients (ITT) n Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo. In favor of atezo + bev In favor of sunitinib 1 Hazard Ratio Presented by: Dr. Thomas Powles
12 Confirmed IRF-Assessed ORR ITT 1% of IC expressing PD-L1 46% 29% 32% 25% 27% 28% PR 5% 7% 11% 7% 12% 15% CR 75% of responses are ongoing across treatment arms, and the median DOR is not estimable due to an insufficient number of PFS events in responders Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo. Presented by: Dr. Thomas Powles
13 All-Cause AEs > 5% difference between arms and at a 20% frequency in either arm Fatigue Diarrhea Nausea Palmar-plantar Mucosal inflammation Dysgeusia Decreased appetite Cough Stomatitis Headache Arthralgia Rash Epistaxis Pyrexia Pruritus Proteinuria 80% + Bevacizumab All-Grade AEs Grade 3-5 AEs Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo. All-Grade AEs Grade 3-5 AEs 60% 40% 20% 0 20% 40% 60% 80% Presented by: Dr. Thomas Powles
14 All-Cause AEs > 5% difference between arms and at a 20% frequency in either arm Fatigue Diarrhea Nausea Palmar-plantar Hypertension Mucosal inflammation Constipation Dysgeusia Decreased appetite Stomatitis Headache Vomiting Rash Pyrexia 80% All-Grade AEs Grade 3-5 AEs Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo. Presented by: Dr. Thomas Powles All-Grade AEs Grade 3-5 AEs 60% 40% 20% 0 20% 40% 60% 80%
15 Transcriptome Map of Angiogenesis and Immune-Associated Genes in RCC Tumors PD-L1 IHC 15 Angiogenesis (e.g., CD34, KDR, VEGFA) PD-L1 IHC IC0 IC1 IC2 IC3 Immune, Antigen Presentation Myeloid Inflammation (e.g. CD8A, IFNG, PSMB8) (e.g. IL6, PTGS2, IL8) Brauer, Clin Cancer Res. 2012; Herbst, Nature 2014; Powles, SITC 2015; Fehrenbacher, Lancet McDermott D, et al. IMmotion150 biomarkers: AACR 2017
16 Demonstrated Improved PFS in Angiogenesis High Subset vs Angiogenesis Low Subset 16 Angiogenesis + Bevacizumab High (n = 44) Low (n = 45) High (n = 45) Low (n = 43) High (n = 42) Low (n = 44) Angiogenesis (High vs Low) HR 95% CI 0.31 (0.18, 0.55) + Bevacizumab HR 95% CI Angiogenesis (High vs Low) 0.90 (0.54, 1.51) HR 95% CI Angiogenesis (High vs Low) 0.74 (0.42, 1.28) Angiogenesis gene signature: VEGFA, KDR, ESM1, PECAM1, ANGPTL4, CD34. Angiogenesis High: median expression, Angiogenesis Low: < median expression. McDermott D, et al. IMmotion150 biomarkers: AACR 2017
17 Demonstrated Improved PFS in Angiogenesis High Subset vs Angiogenesis Low Subset 17 Angiogenesis + Bevacizumab High (n = 44) Low (n = 45) HR (95% CI) 0.31 (0.18, 0.55) High (n = 45) Low (n = 43) High (n = 44) Low (n = 45) High (n = 42) Low (n = 44) Angiogenesis (High vs Low) HR 95% CI 0.32 ( ) Atezo + Bev HR 95% CI Angiogenesis (High vs Low) 0.90 ( ) HR 95% CI Angiogenesis (High vs Low) 0.74 (0.43, 1.29) Angiogenesis gene signature: VEGFA, KDR, ESM1, PECAM1, ANGPTL4, CD34. Angiogenesis High: median expression, Angiogenesis Low: < median expression. McDermott D, et al. IMmotion150 biomarkers: AACR 2017
18 + Bevacizumab Demonstrated Improved PFS vs in the Angiogenesis Low Subset 18 Angiogenesis Angiogenesis Low Atezo + bev (n = 43) Atezo (n = 44) (n = 45) Angiogenesis High Atezo + bev (n = 45) Atezo (n = 42) (n = 44) HR (95% CI) Angiogenesis Low Angiogenesis High Atezo + bev vs sunitinib 0.58 (0.35, 0.98) 1.36 (0.78, 2.36) Atezo vs sunitinib 0.75 (0.45, 1.25) 1.45 (0.81, 2.60) Angiogenesis gene signature: VEGFA, KDR, ESM1, PECAM1, ANGPTL4, CD34. Angiogenesis High: median expression, Angiogenesis Low: < median expression. McDermott D, et al. IMmotion150 biomarkers: AACR 2017
19 Transcriptome Map of Angiogenesis and Immune-Associated Genes in RCC Tumors PD-L1 IHC 19 Angiogenesis (e.g., CD34, KDR, VEGFA) PD-L1 IHC IC0 IC1 IC2 IC3 Immune, Antigen Presentation Myeloid Inflammation (e.g. CD8A, IFNG, PSMB8) (e.g. IL6, PTGS2, IL8) Brauer, Clin Cancer Res. 2012; Herbst, Nature 2014; Powles, SITC 2015; Fehrenbacher, Lancet McDermott D, et al. IMmotion150 biomarkers: AACR 2017
20 and Bevacizumab Demonstrated Improved PFS in T-Effector High Subset vs T-Effector Low Subset 20 Immune + Bevacizumab High (n = 43) Low (n = 46) High (n = 42) Low (n = 46) High (n = 46) Low (n = 40) T-effector (High vs Low) HR 95% CI 1.31 (0.77, 2.23) + Bevacizumab T-effector (High vs Low) HR 95% CI 0.50 (0.30, 0.86) T-effector (High vs Low) HR 95% CI 0.83 (0.48, 1.45) T-effector gene signature: CD8A, EOMES, PRF1, IFNG, CD274. T-effector High: median expression, T-effector Low: < median expression. McDermott D, et al. IMmotion150 biomarkers: AACR 2017
21 and Bevacizumab Demonstrated Improved PFS vs in the T-Effector High Subset 21 Immune T-effector Low Atezo + bev (n = 46) Atezo (n = 40) (n = 46) T-effector High Atezo + bev (n = 42) Atezo (n = 46) (n = 43) HR (95% CI) T-effector Low T-effector High Atezo + bev vs sunitinib 1.41 (0.84, 2.36) 0.55 (0.32, 0.95) Atezo vs sunitinib 1.33 (0.76, 2.33) 0.85 (0.50, 1.43) T-effector gene signature: CD8A, EOMES, PRF1, IFNG, CD274. T-effector High: median expression, T-effector Low: < median expression. McDermott D, et al. IMmotion150 biomarkers: AACR 2017
22 Myeloid Inflammation Immune, Antigen Presentation Angiogenesis Transcriptome Map of Angiogenesis and Immune-Associated Genes in RCC Tumors 22 Myeloid Inflammation PD-L1 IHC T-effector High Subpopulation Tumor cells T-effector cells Myeloid cells Vasculatur e T-effector High Myeloid Inflammation Low T-effector High Myeloid Inflammation High PD-L1 IHC IC0 IC1 IC2 IC3 Brauer, Clin Cancer Res. 2012; Herbst, Nature 2014; Powles, SITC 2015; Fehrenbacher, Lancet McDermott D, et al. IMmotion150 biomarkers: AACR 2017
23 Addition of Bevacizumab to is Associated With Improved Benefit in T-effector High /Myeloid Inflammation High Subgroup Myeloid Inflammation 23 T-effector High Myeloid Low Atezo + bev (n = 23) Atezo (n = 23) (n = 19) T-effector High Myeloid High Atezo + bev (n = 20) Atezo (n = 23) (n = 24) Atezo + bev (n = 20) Atezo (n = 23) (n = 24) T-effector Gene Signature: CD8A, EOMES, PRF1, IFNG, CD274. High: median expression, Low: < median expression. McDermott D, et al. IMmotion150 biomarkers: AACR 2017
24 Conclusions + bevacizumab resulted in encouraging efficacy vs sunitinib in the PD-L1+ subgroup of first-line mrcc patients The data corroborate the clinical activity of atezolizumab monotherapy in first-line mrcc 1 RNAseq gene expression data shows 3 response signatures of clinical relevance. Its also shows bevacizumab and atezolizumab has significant immune activity even in those with resistance to atezo ( high expression of T effector and myeloid signature). Onong RIII studies in will potentially validate these findings. 1. Herbst Nature Presented by: Dr. Thomas Powles
A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients Viktor Grünwald, 1 David McDermott, 2 Michael Atkins, 3 Robert Motzer, 4
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationBiomarcadores em Imuno-Oncologia André P. Fay, MD, PhD
Biomarcadores em Imuno-Oncologia André P. Fay, MD, PhD Professor of Medicine - PUCRS School of Medicine Chief, Medical Oncology Depatrment at HSL/PUCRS Visiting Scientist at Dana-Farber/Harvard Medical
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationBlocking VEGF in addition to checkpoint inhibition in RCC
Blocking VEGF in addition to checkpoint inhibition in RCC Priti S. Hegde, PhD Director, CI Franchise Lead, Biomarkers Genentech/Roche 15 th IKCS Miami, FL The Tumor Immunity Continuum Known factors that
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationRenal Cell Carcinoma: Navigating a Maze of Choices
Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationAtezolizumab Adjuvant Study: Medical Oncologist Perspective. Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center
Atezolizumab Adjuvant Study: Medical Oncologist Perspective Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center Trial overview Key issues Outline Challenges with neoadjuvant therapy Placebo control
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationMedia Release. Basel, 18 February 2017
Media Release Basel, 18 February 2017 Phase II study supports potential for Roche s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
More informationPresenter Disclosure Information
Refractory Renal Cell Cancer (RCC) Exhibits High Adenosine A2A Receptor (A2AR) Expression and Prolonged Survival Following Treatment With the A2AR Antagonist CPI-444 Lawrence Fong, John Powderly II, Jason
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationRenal Cell (RCC) and Bladder Carcinoma (TCC)
Renal Cell (RCC) and Bladder Carcinoma (TCC) Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Disclosures Compensated lectures: BMS, Ipsen,
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationAmreen Husain, 10 Eric P. Winer, 11 Sylvia Adams, 12 Peter Schmid 13
IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naive, locally
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationE2804 The BeST Trial
E2804 The BeST Trial A randomized Phase II Study of VEGF, RAF Kinase and MTOR Combination Targeted Therapy with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma Investigators Keith
More informationMedia Release. Basel, 6 th February 2018
Media Release Basel, 6 th February 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationClinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer
Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer J.R. Brahmer, 1 L. Horn, 2 S.J. Antonia, 3 D. Spigel, 4 L. Gandhi, 5 L.V. Sequist,
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationDISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board
INTERIM ANALYSIS OF THE PHASE 3 ADAPT TRIAL EVALUATING ROCAPULDENCEL-T (AGS-003), AN INDIVIDUALIZED IMMUNOTHERAPY FOR THE TREATMENT OF NEWLY-DIAGNOSED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationRoche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
Media Release Basel, 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Higher expression of PD-L1 (programmed death-ligand 1)
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationCarcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia
Carcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia New target, new agent (James Brugarolas) Atezolizumab + Bevacizumab and PD-L1
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationThe High-Dose Aldesleukin (IL-2) Select Trial in Patients with Metastatic RCC
The High-Dose Aldesleukin (IL-2) Select Trial in Patients with Metastatic RCC D McDermott, M Ghebremichael, S Signoretti, K Margolin, J Clark, J Sosman, J Dutcher, T Logan, R Figlin and M Atkins on behalf
More informationTreatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationAdvances in the Treatment of Renal Cell Carcinoma
Advances in the Treatment of Renal Cell Carcinoma Developed in collaboration Learning Objectives Upon completion, participants should be able to: Identify patients with metastatic renal cell carcinoma
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationLOTUS (NCT ) randomized phase II trial
Overall survival update of the double-blind placebocontrolled randomized phase 2 LOTUS trial of firstline ipatasertib + paclitaxel for locally advanced/metastatic triple-negative breast cancer Rebecca
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationNeratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial
Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial Anishka D Souza 1, Lynda D. Roman 1, Cristina Saura 2, Irene Braña 2, Geoffrey I. Shapiro
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationREAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO
REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO Alain Ravaud, MD.PhD Bordeaux. France DISCLOSURES Consultant for: Pfizer, Novartis, GlaxoSmithKline, Roche, Bristol-Myers Squibb Institutional
More informationRoche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Media Release Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides
More informationImmunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology
Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology 2013: Breakthrough of the Year December 20, 2013 Why immunotherapy? Immune
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic, 1 MR Migden, 2 AE Oro, 3 L Dirix, 4 K Lewis,
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients with advanced cancers
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-211 +/- nivolumab (nivo) in patients with advanced cancers Timothy A. Yap 1, Howard A. Burris 2, Shivaani Kummar 3, Gerald
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationPresenter Disclosure Information
Presenter Disclosure Information Tara C. Gangadhar, M.D. The following relationships exist related to this presentation: Research funding (Institution): Incyte Corporation and Merck & Co., Inc Preliminary
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationLinee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationAngiogenesis Targeted Therapies in Renal Cell Carcinoma
Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T
More informationOverall Survival (OS) Analysis From an Expanded Access Program (EAP) of Nivolumab (NIVO) in Combination with Ipilimumab (IPI) in Patients with Advanced Melanoma (MEL) David Hogg, Paul B. Chapman, 2 Mario
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More information